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Philadelphia chromosome–negative myeloprolifera-
tive neoplasms, including polycythemia vera, essen-
tial thrombocytosis, and myelofibrosis, are disorders
characterized by abnormal hematopoiesis. Among
these myeloproliferative neoplasms, myelofibrosis
has the most unfavorable prognosis. Furthermore,
currently available therapies for myelofibrosis have
little to no efficacy in the bonemarrow and hence, are
palliative. We recently developed a Janus kinase 2
(Jak2) small molecule inhibitor called G6 and found
that it exhibits marked efficacy in a xenograft model
of Jak2-V617F–mediated hyperplasia and a transgenic
mouse model of Jak2-V617F–mediated polycythemia
vera/essential thrombocytosis. However, its efficacy
in Jak2-mediated myelofibrosis has not previously
been examined. Here, we hypothesized that G6 would
be efficacious in Jak2-V617F–mediated myelofibrosis.
To test this, mice expressing the human Jak2-V617F
cDNA under the control of the vav promoter were
administered G6 or vehicle control solution, and effi-
cacy was determined by measuring parameters within
the peripheral blood, liver, spleen, and bone marrow.
858We found that G6 significantly reduced extramedullary
hematopoiesis in the liver and splenomegaly. In the
bone marrow, G6 significantly reduced pathogenic Jak/
STAT signaling by 53%, megakaryocytic hyperplasia by
70%, and the Jak2mutant burden by 68%. Furthermore,
G6 significantly improved the myeloid to erythroid ra-
tio and significantly reversed the myelofibrosis. Collec-
tively, these results indicate that G6 is efficacious in
Jak2-V617F–mediated myelofibrosis, and given its bone
marrow efficacy, it may alter the natural history of this
disease. (Am J Pathol 2012, 181:858–865; http://dx.doi.org/
10.1016/j.ajpath.2012.05.033)
The BCR-ABL1–negative myeloproliferative neoplasms
(MPNs) encompassing polycythemia vera (PV), essential
thrombocythemia (ET), and myelofibrosis have a high prev-
alence in the United States. There are approximately 22
cases of PV, 24 cases of ET, and 1.46 cases of myelofibro-
sis for every 100,000 people, which amounts to approxi-
mately 68,000 patients with PV, 74,000 with ET, and 4500
with myelofibrosis in the United States.1,2 MPNs are char-
acterized by similar pathological syndromes, including ex-
cess production of blood cells from the bone marrow, pru-
ritus, splenomegaly, and extramedullary hematopoiesis.
Among all of the MPNs, myelofibrosis has the most severe
prognosis. It is characterized by profound structural remod-
eling and fibrosis in the bone marrow leading to severe
anemia, weakness, and fatigue. Other characteristics of
myelofibrosis are hypercellularity, osteosclerosis, and
megakaryocytic hyperplasia in the bone marrow.3 The nat-
ural history and structural changes in the marrow contribute
toward the poor prognosis of myelofibrosis and make it a
rather complex disease to treat.
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tations in a large percentage of MPN patients4–8 has re-
sulted in the initiation of molecularly targeted therapies for
the treatment of MPNs. However, despite the high inci-
dence of MPNs in humans and a reasonable understanding
of the molecular mechanisms that underlie these disorders,
currently available therapies are limited. They include cy-
toreductive agents such as hydroxyurea and the pan-
Jak1/2 small molecule inhibitor, ruxolitinib.9 Although these
therapies provide some temporary relief of associated
symptomologies, they are not curative in any way. Further-
more, in the case of ruxolitinib, other than alleviation of
constitutional symptoms, the palliative relief is not durable,
and it has a high discontinuation rate due to a lack of
efficacy characterized by an inability to reduce mutant
clones in the bone marrow or improve patient survival.10,11
Thus, there is still a need to develop molecularly targeted
Jak2 treatment options for MPNs that are effective in elimi-
nating the etiology of the disease within the bone marrow.
We recently developed a small molecule Jak2 inhibitor
called G6.12–14 We demonstrated that it has excellent
therapeutic efficacy in Jak2-V617F–mediated disease
pathogenesis as it significantly reduced or eliminated
mutant cells from the bone marrow using mouse models
of Jak2-V617F–mediated hyperplasia and Jak2-V617F–
mediated PV/ET.15,16 However, its efficacy in Jak2-medi-
ated myelofibrosis has not previously been examined.
The studies described herein were therefore designed to
determine whether G6 could provide therapeutic efficacy
to the bone marrow in a mouse model of Jak2-mediated
myelofibrosis. For this, transgenic mice expressing the
human Jak2-V617F cDNA under the control of the vav
promoter and fully manifesting the myelofibrosis pheno-
type were administered either G6 or vehicle control so-
lution for 28 consecutive days. The mice were then eu-
thanized, and efficacy was determined by performing
postmortem analysis on peripheral blood, liver, spleen,
and bone marrow. We found that in addition to improving a
number of constitutional symptoms associated with myelo-
fibrosis, G6 provided significant therapeutic efficacy in the
bone marrow in the form of a reduced Jak2 mutant burden,
decreased pathogenic Jak/signal transducer and activator
of transcription (STAT) signaling, a significant improvement
of the myeloid to erythroid (M/E) ratio, and a significant
reversal of bone marrow fibrosis. Collectively, these results
indicate that G6 is efficacious in Jak2-V617F–mediated my-
elofibrosis, and given its bone marrow efficacy, it may alter
the natural history of this disease.
Materials and Methods
Animals
All procedures were approved by the Institutional Animal
Care and Use Committee at the University of Florida.
Male mice, 11 to 12 months of age and expressing the
human Jak2-V617F cDNA under the control of the vav
promoter, were used for these experiments. The mice
were generated on a C57BL/6 background strain as pre-
viously described.17 Following acquisition of baseline pe-ripheral blood samples obtained via submandibular
bleeding, the mice were given daily intraperitoneal injec-
tions of either vehicle (n  9) or 10 mg/kg/day of G6 (n 
7) for 28 consecutive days. Terminal peripheral blood
samples were then obtained after 28 days of treatment.
Blood Sample Analysis
Complete blood counts were obtained using a HESKA
Vet ABC-Diff Hematology analyzer (Heska, Loveland,
CO). Peripheral blood smears were also processed using
Dip Quick (Jorgensen Laboratories, Loveland, CO) and
analyzed by a veterinary pathologist.
Histological Analysis
Samples from the liver, spleen, and bone marrow were
fixed in buffered formalin. The samples were then paraffin
embedded and sectioned (4 m). The femurs were de-
calcified for 16 hours before embedding. Tissues sec-
tions were H&E stained and then examined by a board-
certified laboratory animal pathologist who was blinded
to specific treatment groups. Bone marrow evaluation
was completed according to the guidelines established
by Elmore.18 The tissue sections were evaluated for fi-
brosis, cellularity, M/E ratios, megakaryocytic counts,
and extramedullary hematopoiesis (EMH). The bone mar-
row sections were also stained with reticulin (American
MasterTech Scientific, Lodi, CA), and the degree of
fibrosis was rated by a veterinary pathologist who was
blind to specific treatment groups: 0 normal to minimal,
1  minimal to mild, 2  mild to moderate, and 3 
moderate to extensive, as previously described.19 The ret-
iculin staining was also quantified via computer-assisted
morphometric analysis using the NIS-Elements D software
package (Nikon, Tokyo, Japan). Phospho-STAT5 immuno-
histochemistry was carried out on bone marrow sections
using anti–phospho-STAT5 (Ab32364; Abcam, Cambridge,
UK) antibody as previously described.16
Determination of Jak2-V617F Mutant Burden in
the Bone Marrow
Bone marrow samples were obtained from the femur, and
RNA was isolated using the RNeasy Mini Kit (Qiagen,
Valencia, CA). RNase-free DNase was used to eliminate
DNA contamination. cDNA was synthesized from 2 g of
RNA using the high-capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA). Real-time
PCR was carried out in a Multicolor Real-Time PCR Detec-
tion System using TaqMan gene expression assays (Ap-
plied Biosystems). All PCR amplifications were performed in
triplicate for human JAK2 (Hs01078124_m1) and mouse
Jak2 (Mm00434577_m1). Parallel measurements of mouse
-actin cDNA were also done as an internal control, and all
calculations for the copy number of the human Jak2 se-
quence were done relative to -actin. The mutant burden
was calculated by determining the ratio of human Jak2-
V617F to endogenous mouse Jak2-WT transcripts.
fibrosis
860 Kirabo et al
AJP September 2012, Vol. 181, No. 3Statistical Analysis
All results were expressed as mean  SEM. Statistical
comparisons were done using the Student’s t-test as well
as a repeated measures analysis of variance followed by
Bonferroni and Student-Newman-Keuls post hoc tests for
multiple comparisons. P values of 0.05 were consid-
ered statistically significant.
Results
Effect of G6 on the Peripheral Blood of
Myelofibrosis Mice
Myelofibrosis is a complex disease that presents variable
clinical features, including anemia, extramedullary hemato-
poiesis, splenomegaly, myeloid hyperplasia, and marrow
fibrosis. To determine whether G6 has therapeutic efficacy
in the treatment of myelofibrosis, we used mice expressing
the human Jak2-V617F cDNA in hematopoietic tissues.17
These mice exhibit most of the phenotypic syndromes as-
sociated with myelofibrosis and constitutive Jak2 signaling.
Baseline peripheral blood counts were obtained, and the
mice were then randomly assigned to one of the two
groups: vehicle control or G6 treatment. Examination of the
baseline samples revealed significant variations in the dif-
ferent cellular components when compared to nontrans-
genic mice (Table 1). Peripheral blood samples were again
obtained after 28 days of either vehicle or G6 treatment, and
despite the high variability in the counts, one significant
observation was that myelofibrosis mice receiving vehicle
control solution experienced an anemic effect during the
28-day treatment period characterized by a 38% decrease
in red cell counts, a 30% decrease in hemoglobin, and a
36% decrease in hematocrit levels (Table 1). Although my-
elofibrosis mice receivingG6 also experienced anemia over
the same 28-day treatment period, the effect was signifi-
cantly less severe from that observed in mice receiving
vehicle control solution, namely, an 18% decrease in red
cell counts, a 9% decrease in hemoglobin, and a 15%
decrease in hematocrit levels.
G6 Reduces Extramedullary Hematopoiesis in
Jak2-V617F–Mediated Myelofibrosis
Jak2-V617F–mediated myelofibrosis is often associated
with increased EMH in the liver. Here, we wanted to
determine whether G6 could demonstrate therapeutic ef-
Table 1. Summary of Peripheral Blood Analyses of Wild-Type a
PMF
Wild type Vehicle
PLT (K/L) 1308  304 2189  455
WBC (K/L) 8.23  1.62 30.40  8.86
RBC (M/L) 9.34  0.61 13.26  2.81
HB (g/dL) 12.23  1.04 13.61  2.19
HCT (%) 43.89  2.50 50.95  7.90
Values are means  SEM.
*P  0.05 in reference to baseline measurements.
HB, hemoglobin; HCT, hematocrit; PLT, platelets; PMF, primary myeloficacy by reducing the number of EMH sites in this tissue.Figure 1A shows representative H&E-stained liver sec-
tions from the indicated groups, and Figure 1B shows the
average number of EMH sites per field, plotted as a
function of treatment group. We found that when com-
pared to wild-type mice, myelofibrosis mice treated with
vehicle control solution had a 600% increase in the number
of EMH sites per field in the liver, and this was reduced by
nearly one half with G6 treatment.
G6 Alleviates Splenomegaly and
Megakaryocytic Hyperplasia in the Spleen
Splenomegaly is one of the clinical features associated
with myelofibrosis, and the transgenic mice expressing
the Jak2-V617F mutation similarly exhibit this character-
istic.17 To determine whether G6 was efficacious in re-
icle- or G6-Treated Myelofibrosis Mice
ine PMF 28 days
G6 Vehicle G6
2185  376 2079  930 2697  566
17.84  8.53 19.52  12.40 26.20  11.31
10.88  1.44 8.16  3.37* 8.92  2.13
10.98  1.87 9.51  4.16* 9.98  1.72
41.56  6.15 32.8  13.78* 35.26  5.22
; RBC, red blood cells; WBC, white blood cells.
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Figure 1. G6 relieves extramedullary hematopoiesis in Jak2-V617F–medi-
ated myelofibrosis (MF). A: H&E stained liver sections showing extramedul-
lary hematopoiesis sites at the indicated magnifications (yellow arrows). B:nd Veh
baselThe average number of extramedullary hematopoiesis sites plotted as a
function of treatment group. *P  0.05 versus wild type.
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AJP September 2012, Vol. 181, No. 3ducing the spleen size in these mice, we determined the
spleen-weight to body-weight ratios in wild-type mice,
myelofibrosis mice treated with vehicle, and myelofibro-
sis mice treated with G6. Figure 2A shows representative
spleens from each condition, and Figure 2B shows the
spleen-weight to body-weight ratios plotted as a function
WT MF + Vehicle MF + G6
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Figure 2. G6 alleviates splenomegaly and megakaryocytic hyperplasia in the
spleen. A: Representative spleens from the indicated conditions. B: Average
spleen-weight to body-weight ratios plotted as a function of treatment group. C:
H&E-stained histological sections of the spleens at the indicated magnifications
showing megakaryocytic hyperplasia in the myelofibrosis (MF) mice treated
with vehicle control solution. D: Average number of megakaryocytes per high-
power field plotted as a function of treatment group. *P  0.05 versus vehicle-
treated myelofibrosis mice; **P  0.001 versus wild type.of treatment group. We found that when compared to wild-type mice, myelofibrosis mice treated with vehicle solution
had a250% increase in the spleen-weight to body-weight
ratios, and this was significantly reduced with G6 treatment.
Figure 2C shows representative H&E-stained spleens from
each condition, and Figure 2D indicates the number of
megakaryocytes per high-power field plotted as a function
of treatment group. We found that when compared to wild-
type mice, the spleens from myelofibrosis mice treated with
vehicle control solution had a 150% increase in the number
of megakaryocytes per field, and this was significantly re-
duced with G6 treatment.
G6 Alleviates Megakaryocytic and Myeloid
Hyperplasia in the Bone Marrow
Myelofibrosis is often characterized by marrow megakaryo-
cytic and myeloid hyperplasia.3 As a consequence, bone
marrow biopsies from myelofibrosis patients usually exhibit
an abnormal M/E ratio. To gain some understanding of the
potential efficacy of G6 in the bone marrow, histological
sections were prepared from each mouse and examined.
Figure 3A shows representative sections for each condition.
10X
40X
WT MF + Vehicle MF + G6A
B
C
0
2
4
6
8
10
12
14
16
18
WT MF + Vehicle MF + G6
**
*
M
ar
ro
w
 M
eg
ak
ar
yo
cy
te
s/
H
P
F 
M
ar
ro
w
 M
eg
ak
ar
yo
cy
te
s/
H
P
F 
M
:E
 R
at
io
WT MF + Vehicle MF + G6
**
*
0
1
2
3
4
5
6
7
8
9
10
M
:E
 R
at
io
Figure 3. G6 alleviates megakaryocytic and myeloid hyperplasia in the bone
marrow. A: Representative H&E-stained bone marrow sections showing the
effect of G6 on megakaryocytic hyperplasia. B: Average number of mega-
karyocytes per high-power field in each treatment group. C: Average M/E
ratios of each condition. *P  0.05 versus vehicle-treated myelofibrosis (MF)
mice; **P  0.001 versus wild type.
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brosis mice treated with vehicle control solution were found
to have marked megakaryocytic hyperplasia and myelofi-
brosis, and this was reversed with G6 treatment. To quantify
these results, the numbers of megakaryocytes per high-
power field were plotted as a function of condition (Figure
3B). We found that when compared to the wild-type mice,
the myelofibrosis mice treated with vehicle control solution
had a 200% increase in the number of megakaryocytes
per high-power field, andG6 significantly reduced this num-
ber. Furthermore, when compared to wild-type controls, the
M/E ratio in the myelofibrosis mice was increased 250%,
and this too was significantly reduced with G6 treatment
(Figure 3C).
G6 Reduces Bone Marrow Reticulin Fibrosis
Myelofibrosis is characterized clinically by scarring of the
bone marrow, and this is a major contributor to the poor
prognosis in patients affected by this condition. Thus,
identification of drugs that can reverse this deleterious
outcome could significantly improve prognosis. To deter-
mine whether G6 reduces bone morrow fibrosis in this
model, we carried out reticulin staining of the bone mar-
row sections of wild-type mice, myelofibrosis mice
treated with vehicle control solution, and myelofibrosis
mice treated with G6. Figure 4A shows representative
images of the reticulin staining at 40 and 100 magni-
fications. Qualitatively, the myelofibrosis mice treated
with vehicle control solution exhibited marked reticulin
staining, and this was greatly reduced in the G6-treated
mice. To quantify these data, we used two independent
approaches. First, we measured the levels of reticulin
stain using computer-assisted morphometric analysis.
Second, we determined the levels of fibrosis via a stan-
dardized pathological index score. We found that when
compared to age-matched wild-type controls, bone mar-
row sections obtained from myelofibrosis mice treated
with vehicle control solution had significantly elevated
levels of both reticulin stain (Figure 4B) and pathological
index score (Figure 4C). However, G6 treatment signifi-
cantly reduced these two parameters in the myelofibrosis
mice (Figure 4, B and C).
G6 Reduces Phosphorylation of STAT5 in the
Bone Marrow
Aberrant Jak/STAT signaling is a hallmark of Jak2-
V617F–driven MPNs, including myelofibrosis. Here, we
wanted to determine whether treatment with G6 reduces
the increased activation of the Jak/STAT signaling path-
way as indicated by phosphorylation of the proliferative
marker STAT5. To this end, we carried out anti–phospho-
STAT5 immunohistochemistry staining of the bone mar-
row sections from wild-type, myelofibrosis mice treated
with vehicle, and myelofibrosis mice treated with G6.
Figure 5A shows representative images of the anti–phos-
pho-STAT5 immunohistochemistry at 40 and 100
magnifications. Qualitatively, we found that the bone
marrow sections from the myelofibrosis mice treatedwith vehicle control solution had a significant increase
in phospho-STAT5 staining when compared to the
wild-type mice, and this was reduced with G6 treat-
ment. To quantify these data, computer-assisted mor-
phometric analysis was used, and the relative amounts
of anti–phospho-STAT staining were plotted as a func-
tion of treatment group (Figure 5B). We found that G6
treatment resulted in a 53% reduction in the amount of
phospho-STAT5 signal in the bone marrow, and this
was significant.
G6 Significantly Reduces the Jak2-V617F
Mutant Burden in the Bone Marrow
Several Jak2 inhibitors have been tested in mouse mod-
els of Jak2-V617F–mediated MPNs. However, these in-
hibitors are limited by their inability to decrease the Jak2-
V617F mutant burden in the bone marrow.20–22 To
assess this in our model using G6, we measured the
levels of mutant Jak2-V617F transcripts and endogenous
Jak2-WT mouse transcripts in the bone marrow. Figure 6A
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Figure 4. G6 reduces bone marrow reticulin fibrosis in a mouse model of
Jak2-V617F–mediated myelofibrosis (MF). A: Representative images of the
reticulin staining at the indicated magnifications. B: Relative reticulin staining
as determined by computer-assisted morphometric analysis. C: Relative ret-
iculin fibrosis using a standardized pathological fibrotic index score. *P 
0.05 versus vehicle-treated myelofibrosis mice; **P  0.001 versus wild type.shows that G6 treatment reduced the levels of mutant Jak2
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AJP September 2012, Vol. 181, No. 3transcripts by 75% when compared to myelofibrosis mice
that received vehicle control solution. To determine
whether this reduction was due to nonspecific elimination
of cells from the marrow by G6, we also measured the
levels of endogenous Jak2-WT mRNA transcripts (Figure
6B). We found that G6 treatment slightly reduced the
levels of Jak2-WT mRNA, but this was not significantly
different from myelofibrosis mice that received vehicle
control solution. Consequently, we found that the mutant
burden, defined as the ratio of the mutant Jak2-V617F to
endogenous wild-type Jak2 mRNA transcripts, was re-
duced by 68% with G6 treatment, and this was significant
(Figure 6C).
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Figure 5. G6 reduces phosphorylation of STAT5 in the bone marrow. A:
Representative images of anti–phospho-STAT5 immunohistochemistry at the
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ing plotted as a function of treatment group. *P  0.05 versus vehicle-treated
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MPNs are a group of related diseases that are charac-
terized by a dysregulated clonal myeloproliferation result-
ing in excess production of terminally differentiated blood
cells. Myelofibrosis has the most unfavorable natural his-
tory and worst prognosis of the MPNs because of the
structural changes that occur in the bone marrow. Al-
though currently available therapies alleviate symptom-
ologies such as splenomegaly, abnormal blood counts,
and/or reduction of inflammatory cytokines, unfortunately,
they lack bone marrow efficacy in the form of histopatho-
logic, cytogenetic, or molecular remissions. Given this
current backdrop, it is not surprising that there are con-
tinued calls for the further development of Jak2 small
molecule inhibitors with particular emphasis on bone
marrow efficacy.23,24 In addition to demonstrating effi-
cacy in the form of amelioration of anemia, reduced EMH,
and reduced splenomegaly, we demonstrate here signif-
icant bone marrow efficacy characterized by a 70% re-
duction in megakaryocytic hyperplasia, a significant cor-
rection of the M/E ratio, a 53% reduction in pathogenic
phospho-STAT5 signaling, a 68% reduction in the Jak2
mutant burden, and a 67% decrease in the amount of
reticulin staining. When taken together, these data indi-
cate an overall improvement in the bone marrow and a
significant reversal of myelofibrosis.
We recently reported that G6 is very efficacious in
eliminating the Jak2 mutant burden from the bone mar-
row in a human erythroleukemia cell xenograft model of
Jak2-V617F–mediated hyperplasia. Specifically, G6 at
doses of 1 mg/kg/day and 10 mg/kg/day decreased the
mutant burden by 90% and 95%, respectively.15 Al-
though the human erythroleukemia cell xenograft model
exhibited many of the bone marrow pathologies ob-
served in Jak2-V617F–positive patients such as a low
mutant burden in the context of the marrow niche, it was
limiting in that it lacked someMPN features such as myeloid
neoplasia. More recently, we demonstrated G6 bone mar-
row efficacy using amousemodel of Jak2-V617F–mediated
PV/ET.16 Although this model manifested marked myeloid
neoplasia, it lacked major deleterious structural changes in
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study, we used a transgenic mouse model of Jak2-V617F
myelofibrosis to determine whether G6 could reverse the
damaging structural changes in the bone marrow. In con-
junction with the two previously published models, our data
here in the form of repeated measures of bone marrow
efficacy, with particular emphasis on significantly reduced
bone marrow fibrotic index scores, indicate that G6 facili-
tates disease remission.
Another important aspect of this work is the continued
ability of G6 to exhibit in vivo efficacy. Although a number
of previous Jak2 small molecule inhibitors demonstrated
Jak2 inhibitory potential in vitro, those inhibitory potentials
failed to fully manifest themselves when the compounds
were tested in vivo. For example, INCB18424 (Ruxolitinib/
Jakafi), CYT387, CEP-701, and INCB16562 all demon-
strated good in vitro efficacy, but had limited efficacy in
vivo.20,21,25,26 The demonstration here that Jak2 pos-
sesses marked in vivo efficacy using a third model of
Jak2-mediated disease is significant and underscores
the possibility that this compound may be efficacious in
some human disorders that are caused by aberrant Jak2
signaling.
Perhaps the most significant observations of this work
are the reductions in the Jak2 mutant burden and the
reductions in the myelofibrosis. Comparison of the cur-
rent G6 data with that of other Jak2 inhibitors is notable.
For instance, we demonstrate here that IP administration
of G6 at 10 mg/kg/day reduced the Jak2 mutant burden
by 68% (Figure 6). By contrast, oral administration of the
Jak2 inhibitor CYT387 at doses of 50 and 100 mg/kg/day
had no reported effect on mutant burden in the bone
marrow.21 In the case of ruxolitinib, initiating an oral dose
of 180 mg/kg/day on the same day that Jak2-V617F cells
were implanted into the bone marrow of recipient mice
reduced the Jak2 mutant burden by only 33%, indicating
that this drug modestly prevents engraftment of Jak2
mutant cells into the marrow.20 In instances where human
Jak2-dependent disease was fully established in the mar-
row before treatment with ruxolitinib was initiated, the
drug had no effect on bone marrow mutant burdens.9
Lastly, oral administration of TG101348 at doses of 120
and 240 mg/kg/day reduced the Jak2 mutant burden in
the marrow by 0% and 67%, respectively.22 We are, of
course, aware that G6 was administered via i.p. injection,
whereas the others were delivered orally, and this can
explain some of the observed differences in efficacy.
However, we also realize that G6 has the potential to
significantly impact the bone marrow in terms of reduced
mutant burdens, whereas these other compounds are
restricted. With respect to the improvement of myelofibro-
sis, Jak2 inhibitors that have been studied in preclinical
and clinical trials have been very limited in this regard. In
the case of ruxolitinib, it has no effect in the bone marrow,
and hence, it cannot alter the natural history of myelofi-
brosis.9 Furthermore, other than alleviation of constitu-
tional symptoms, the palliative relief of this drug is not
durable, and it has a high discontinuation rate due to a
lack of efficacy characterized by an inability to reduce
mutant clones in the bone marrow or improve patient sur-
vival.10,11 This in part has fueled calls for the development ofJak2 inhibitors that can halt or even reverse fibrosis.23,24 We
show here that G6 significantly reduced both the reticulin
stain and the fibrotic index score of mice when compared to
mice that received vehicle control solution (Figure 4). As
such, our results demonstrate that the seemingly irrevers-
ible structural damage in the bone marrow of these mice is
reversed with G6.
Putative Jak2 inhibitors comprise a number of diverse
chemical structures including tyrphostins, pyrazines, py-
rimidines, azaindoles, aminoindazoles, deazapurines,
benzoxazoles, and quinoxalines.27 G6 is the only known
Jak2 inhibitor belonging to a group of diarylethene com-
pounds known as stilbenoids. Stilbenoids are naturally oc-
curring compounds found in a wide variety of plants, such
as grapes, and they act to defend against disease patho-
gens and DNA damage in the form of UV exposure.28
Within animals, stilbenoids provide therapeutic benefit to
pathological conditions such as inflammation, cancer, oxi-
dative stress, cardiovascular diseases, and viral diseas-
es.29–31 Stilbenoids have also been reported to inhibit ty-
rosine kinases such as LMP2.32,33 However, no study has
reported any therapeutic efficacy of stilbenoid compounds
in myelofibrosis. We believe the ability of G6 to demonstrate
in vivo efficacy in the form of decreased Jak2/STAT signal-
ing and reduced myelofibrosis may lie in its unique chem-
ical scaffold and its reactive groups.12,13 Furthermore,
given that stilbenoids are naturally occurring, they generally
have low toxicity profiles. This is supported in this current
work in that myelofibrosis mice that were treated with G6
displayed no histopathologies beyond those observed in
the hematopoietic tissues that were consistent with consti-
tutive Jak2 signaling. As such, this absence of cytotoxicity
suggests that G6 may be well tolerated in humans.
In conclusion, we show that the small molecule stilbenoid
Jak2 inhibitor, G6, provides therapeutic efficacy in a mouse
model of Jak2-mediated myelofibrosis by resolving the con-
siderable structural remodeling in the bone marrow. This
therapeutic efficacy was also accompanied by a significant
reduction in the Jak2 mutant burden and an elimination or
alleviation of a number of associated symptomologies. As
such, these results suggest that G6 may be therapeuti-
cally potent in altering the natural history of myelofibrosis
and, therefore, may be a viable candidate for progression
into clinical trials for the treatment of this debilitating
disorder.
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